Q1 Earnings Estimate for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Alumis in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($1.46) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

A number of other research analysts also recently issued reports on ALMS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price (down from $19.00) on shares of Alumis in a research report on Thursday, March 20th. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Stock Up 0.8 %

Shares of ALMS opened at $3.78 on Tuesday. The stock has a 50 day moving average of $5.62 and a 200 day moving average of $8.49. Alumis has a 12 month low of $3.18 and a 12 month high of $13.53.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in shares of Alumis in the third quarter valued at $27,000. Wells Fargo & Company MN increased its position in shares of Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after buying an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alumis in the fourth quarter worth about $79,000. MetLife Investment Management LLC purchased a new position in Alumis during the third quarter valued at approximately $89,000. Finally, Marshall Wace LLP purchased a new position in Alumis during the fourth quarter valued at approximately $108,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.